Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2024-12-02 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued shares and treasury shares of a listed company, including share issuance under equity plans and share repurchases. It references specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM) sections 13.25A, 17.27A, 10.06(4)(a), and others, which govern disclosure of share capital changes. The document includes tables of share counts before and after events, prices per share, and confirmations of compliance with regulatory requirements. It is not an announcement of a report publication but the actual disclosure itself. The content matches the description of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document length is 4190 characters, which is sufficient for a detailed disclosure but not a full annual or interim report. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2024-12-02 Chinese
百济神州有限公司自愿披露关于商业化产品多项适应症纳入新版国家医保药品目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 百济神州有限公司 (BeiGene Ltd.) regarding the inclusion of multiple indications of its commercialized products into the new National Medical Insurance Drug List effective January 1, 2025. It details the products, their indications, and the impact on the company. There are no financial statements, no quarterly or annual financial data, no earnings highlights, no management discussion of financial results, no regulatory certifications, no voting results, no share transactions, no merger or acquisition information, and no legal proceedings. The document is a regulatory announcement about product listing and reimbursement status, which is a general regulatory announcement. The document length is 3184 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-11-28 Chinese
港股公告：翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is a detailed disclosure report about changes in issued shares and treasury shares, including share issuance due to stock options exercised by a director, and confirmations related to compliance with Hong Kong Stock Exchange listing rules. It references specific listing rule sections (e.g., Main Board Listing Rule 13.25A, GEM Listing Rule 17.27A) and provides detailed tables of share movements and confirmations. The document is not a full financial report but a regulatory disclosure about share capital changes and share repurchases. It is not an announcement of a report but the actual disclosure itself. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchases, issuances, or sales of treasury shares. The document length (4029 characters) and content confirm it is a substantive disclosure, not just a brief announcement or certification. Therefore, the correct classification is POS with high confidence.
2024-11-27 Chinese
港股公告：授出购股权及受限制股份单位
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the grant of share options and restricted share units under the 2016 Option and Incentive Plan. It details the number of shares granted, exercise prices, vesting schedules, and other terms related to equity compensation. The document references compliance with listing rules and provides definitions related to the equity awards. There is no financial statement, earnings data, or management discussion of financial results. The content focuses on the issuance of share-based incentives to employees, which is a capital change event related to share issuance. The document length is 3786 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Share Issue/Capital Change (SHA).
2024-11-19 Chinese
美股公告：临时报告8-K表格
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC), which is a current report used to announce major events that shareholders should know about. The text includes references to the Securities Exchange Act of 1934, the form type 8-K, and specific event disclosures such as a patent litigation settlement and withdrawal of lawsuits. It does not contain comprehensive financial statements or detailed financial analysis, but rather reports a significant legal event and settlement. The document length is 2530 characters, which is relatively short and consistent with an 8-K filing. Therefore, this is a Regulatory Filing (RNS) as it is a current report disclosing material events but not a full financial report or other specialized filing.
2024-11-19 Chinese
百济神州有限公司关于拟议变更公司英文名称的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company's board regarding a proposed change in the company's English name and the change of its place of registration. It mentions the board's approval and the need for shareholder meeting approval. The document is short (906 characters) and primarily serves as a notification of a corporate action rather than a detailed report or financial statement. There is no financial data, no detailed report, no voting results, and no regulatory certification. It is an announcement about a corporate governance change (name and registration change) but does not detail board or management personnel changes. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-11-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.